Rahul Dhanda is co-founder, CEO, and director of Syntis Bio. He is also the co-founder and chairman of BLASTID, Inc., a spinout of Harvard Medical School funded through ARPA-H, which awarded the largest grant ever received by the institution. Additionally, Rahul serves as an independent director at Constructive Bio.

Prior to Syntis, Rahul co-founded Sherlock Biosciences, where he served as CEO, president, and director from inception to launching the first-ever CRISPR product, diagnostic or therapeutic, authorized by the FDA. Under his leadership, Sherlock was recognized as a Fast Company Most Innovative Company (Top 10 in Biotech), a Red Herring Top 100 Company, Fierce15 MedTech, a Tech Pioneer by the World Economic Forum, and a Top 50 Innovative Company by BostonInno, among others. Rahul was also named to Boston’s Power50 list by the Boston Business Journal in 2020.

Rahul spent over a decade at T2 Biosystems in critical roles that led the company to become a publicly-traded, commercial leader in infectious disease diagnostics. As Senior Vice President of Corporate Development and Marketing, he spearheaded multiple strategic and commercial initiatives, including marketing, product management, and over $40 million in partnering deals.

Rahul holds an MBA from MIT’s Sloan School of Management and a B.A. from Wesleyan University. He is the author of “Guiding Icarus: Merging Bioethics with Corporate Interests,” the first book addressing the intersection of industry and bioethics/public policy. Rahul is also an inventor on numerous patents and has authored several publications.